December 13, 2017

Sanofi presents R&D strategy and innovative pipeline ​


Sanofi presents R&D strategy and innovative pipeline 

  • Robust pipeline expected to support long-term growth
  • 9 planned regulatory submissions over next 18 months
  • At least 10 pivotal phase 3 studies expected to begin over next 12 months
  • R&D model leverages new proprietary technology platforms,
    multi-targeting molecules and biologics

PARIS, France – 13 December 2017 – Sanofi will host an analyst meeting in Paris today to discuss the company’s Research and Development strategy, development pipeline and milestones for 2018. The company will highlight the progress it has made against “Sustaining Innovation”, a key pillar of its 2020 strategic roadmap, and advancing a differentiated portfolio addressing unmet needs.

The company’s pipeline spans 71 R&D projects, which includes 37 new molecular entities and novel vaccines. At least 10 pivotal phase 3 studies are expected to start over the next 12 months and will evaluate new treatments for:

  • chronic obstructive pulmonary disease and eosinophilic esophagitis (dupilumab[4] amyloidosis and fitusiran for hemophilia A and B, with and without inhibitors.

    Diabetes & Cardiovascular

    Sanofi is committed to sustaining a leadership position in diabetes and expanding into adjacent co-morbidities. Its late-stage diabetes pipeline includes sotagliflozin, an investigational SGLT-1/2 inhibitor being developed in collaboration with Lexicon, and efpeglenatide, a once-weekly GLP-1 being developed in collaboration with Hanmi, both of which potentially offer unique patient advantages. Additionally, Sanofi is leveraging its novel peptide incretin platform to develop breakthrough assets for diabetes, obesity and non-alcoholic steatohepatitis (NASH). The lead compound is a dual agonist of GLP-1/GCG which has shown highly competitive weight loss in the clinic and is expected to enter phase 3 in obesity in 2018. A phase 2 study in NASH is also due to start in 2018.

    In cardiovascular, Sanofi continues to work in collaboration with Myokardia on therapeutic options for genetic forms of cardiomyopathy. The lead compound is mavacamten, an oral modulator of cardiac myosin, which is in phase 2 for HCM[3] The Principia transaction remains subject to customary regulatory approvals and has not yet closed.